^
Association details:
| Biomarker: | RANBP2-ALK fusion |
|---|---|
| Cancer: | Soft Tissue Sarcoma |
| Drug: | doxorubicin hydrochloride (Topoisomerase II inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
A Case Report of Epithelioid Inflammatory Myofibroblastic Sarcoma with RANBP2-ALK Fusion Gene Treated with the ALK Inhibitor, Crizotinib
Excerpt:
...22-year-old Japanese man with a...epithelioid inflammatory myofibroblastic sarcoma with RANBP2-ALK fusion….The patient received doxorubicin at a dose of 70 mg/m2 from May 2013 as palliative chemotherapy. CT imaging performed after one cycle of therapy showed further growth of the metastatic and peritoneal lesions...
DOI:
10.1093/jjco/hyu069
